New drug cocktail aims to shrink aggressive breast tumors before surgery

NCT ID NCT07371208

Recruiting now Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing a combination of two drugs—Sac-TMT (a targeted chemotherapy) and KL-A167 (an immunotherapy)—given before surgery to 40 people with triple-negative breast cancer. The goal is to see if the combo can eliminate or shrink tumors enough to improve long-term outcomes. Participants will receive the drugs for 12 to 24 weeks, then have surgery to assess response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab tirumotecan (Sac-TMT) and KL-A167 (a PD-L1 inhibitor)
What this could lead to: If successful, this combination could shrink tumors before surgery, potentially improving outcomes for people with triple-negative breast cancer.
What could go wrong: This is a small, early-phase trial (40 people) with no control group, so results may not apply broadly. Side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.